Key facts
- Mosanna Therapeutics’s last known valuation is $10.2M (Apr 2023).
- It has raised $101.2M; the latest was Early Stage VC ($95.0M) in Dec 2025.
- Notable investors include High-Tech Gründerfonds, Norwest, Forbion, EQT Life Sciences, Norwest Holdings — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Mosanna Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Mosanna Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Mosanna Therapeutics
Provider of biotech services intended to improve patient outcomes and quality of life in high unmet need diseases, applying a precision medicine approach. The company specializes in developing medicinal nasal sprays and carefully selects innovative medicines for further development using the best contract research organizations in the specific specialized field, enabling hospitals and doctors to cure patients suffering from the disease.
- Sector
- Healthcare
- HQ
- Redwood City, CA, United States
- Founded
- 2022
- Employees
- 8
- Website
- mosanna.com/
- Ownership
- Privately Held (backing)
Mosanna Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mosanna Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mosanna Therapeutics in its N-PORT filings yet. We sweep new filings monthly.